Cosmetic Ingredient Review Report Status
This article was originally published in The Rose Sheet
Executive Summary
Chart: Data compiled by the Rose Sheet from information in CIR reports following the Expert Panel's Dec. 4-5 meeting.
You may also be interested in...
CIR: Industry Working On Producing Preservative PHMB Sensitization Data
The Cosmetic Ingredient Review Expert Panel issued final safety conclusions for five ingredients at its Dec. 4-5 meeting, as well as six tentative reports and two insufficient data announcements. According to a post-meeting recap, industry is working to complete a sensitization study for preservative polyaminopropyl biguanide at the panel's request.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.